Compare ULCC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | BBOT |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2017 | N/A |
| Metric | ULCC | BBOT |
|---|---|---|
| Price | $3.38 | $9.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $5.44 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.6M | 237.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,724,000,000.00 | N/A |
| Revenue This Year | $21.62 | N/A |
| Revenue Next Year | $12.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $8.70 |
| 52 Week High | $6.66 | $14.87 |
| Indicator | ULCC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 28.26 | 34.72 |
| Support Level | $3.20 | $8.80 |
| Resistance Level | $4.24 | $12.36 |
| Average True Range (ATR) | 0.24 | 0.57 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 4.76 | 12.39 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.